Data from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8<sup>+</sup> T Cells and Enhances the Efficacy of Anti-PD1 Blockade

<div>AbstractPurpose:<p>To overcome the limited efficacy of immune checkpoint blockade, there is a need to find novel cancer immunotherapeutic strategies for the optimal treatment of cancer. The novel anti–4-1BB×PDL1 bispecific antibody—ABL503 (also known as TJ-L14B)—was designed to simultaneously target PDL1 and 4-1BB and demonstrated strong antitumor T-cell responses without considerable toxicity. In this study, we investigated the mechanisms by which the combination of ABL503 and anti-PD1 blockade affected the reinvigoration of exhausted tumor-infiltrating CD8⁺ T cells (CD8⁺ TIL) and antitumor efficacy.</p>Experimental Design:<p>Single-cell suspensions of hepatocellular carcinoma and ovarian cancer tissues from treatment-naïve patients were used for immunophenotyping of CD8⁺ TILs and <i>in vitro</i> functional assays. Humanized hPD1/hPDL1/h4-1BB triple–knock-in mice were used to evaluate the effects of ABL503 and anti-PD1 blockade <i>in vivo</i>.</p>Results:<p>We observed that ABL503 successfully restored the functions of 4-1BB⁺ exhausted CD8⁺ TILs, which were enriched for tumor-specific T cells but unresponsive to anti-PD1 blockade. Importantly, compared with anti-PD1 blockade alone, the combination of ABL503 and anti-PD1 blockade further enhanced the functional restoration of human CD8⁺ TILs <i>in vitro</i>. Consistently, the combination of ABL503 with anti-PD1 <i>in vivo</i> significantly alleviated tumor growth and induced enhanced infiltration and activation of CD8⁺ TILs.</p>Conclusions:<p>ABL503, a PDL1 and 4-1BB dual-targeting bispecific antibody, elicits pronounced additive tumor growth inhibition, with increased infiltration and functionality of exhausted CD8⁺ T cells, which in turn enhances the anticancer effects of anti-PD1 blockade. These promising findings suggest that ABL503 (TJ-L14B) in combination with PD1 inhibitors will likely further enhance therapeutic benefit in clinical trials.</p><p><i><a href="https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-24-1568" target="_blank">See related commentary by Molero-Glez et al., p. 3971</a></i></p></div>